Last reviewed · How we verify
NCT03743480: EPC-EMA1
Early Palliative Care and Hematological Cancer Patients
NA trial testing early palliative care in Hematologic Neoplasms in 15 participants. Terminated before completion.
26 October 2021
Quick facts
| Lead sponsor | Azienda USL Reggio Emilia - IRCCS |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 15 |
| Start date | 21 November 2018 |
| Primary completion | 26 October 2021 |
| Estimated completion | 26 October 2021 |
| Sites | 2 locations across Italy |
Drugs / interventions tested
- early palliative care
Conditions studied
- Hematologic Neoplasms — all drugs for Hematologic Neoplasms →
Sponsor
Azienda USL Reggio Emilia - IRCCS — full company profile →
Who can join
18 and older, any sex, with Hematologic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to pilot and evaluate a new integration model between a Specialised Palliative Care (SPC) intervention and standard hematological care in an Italian hospital. This is a feasibility mix-methods study, where a sample of advanced hematological patients are randomised to receive integrated hematological care and a SPC intervention or standard hematological care throughout the course of the predictive last active treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03743480
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of early palliative care
Trials testing the same drug.
- NCT04415190 — the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients · unknown
Other recruiting trials for Hematologic Neoplasms
Currently open trials in the same condition.
- NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
- NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
- NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
- NCT06685848 — Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion · NA · recruiting
- NCT06433349 — A Multi-center Investigation of Family Health. · recruiting
Other Azienda USL Reggio Emilia - IRCCS trials
Trials by the same sponsor.
- NCT07373626 — Physical Activity Trends in Cancer Survivors Treated at the 'MOvement and REhabilitation' Clinic · recruiting
- NCT07000162 — LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial · Phase 2 · recruiting
- NCT06629896 — Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomize · NA · recruiting
- NCT06749600 — Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma · recruiting
- NCT06624280 — Does Orthopedic Surgery Improve Gait Efficiency in Children With Cerebral Palsy? A Retrospective Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03743480 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda USL Reggio Emilia - IRCCS
- Last refreshed: 25 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03743480.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing